Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,516.00
Bid: 12,554.00
Ask: 12,556.00
Change: 112.00 (0.90%)
Spread: 2.00 (0.016%)
Open: 12,500.00
High: 12,586.00
Low: 12,444.00
Prev. Close: 12,404.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: Stocks start second half in green amid PMIs

Mon, 03rd Jul 2023 09:07

(Alliance News) - European markets rose at Monday's open, kicking off the start of the second half on a positive note, boosted by strong trading in Asia and New York,

The FTSE 100 index opened up 18.52 points, 0.3%, at 7,550.05. The FTSE 250 was up 72.89 points, 0.4%, at 18,489.65, and the AIM All-Share was up 0.65 point, 0.1%, at 754.16.

The Cboe UK 100 was up 0.2% at 753.09, the Cboe UK 250 was up 0.3% at 16,141.46, and the Cboe Small Companies was up 0.1% at 13,727.97.

"The FTSE 100 opened marginally higher, helped by the tailwinds of a strong session in Asia and on Wall Street on Friday. But it's still struggling to find significant momentum, dragged down by concerns about growth in China and the wider global economy," commented Hargreaves Lansdown's Susannah Streeter.

In European equities, the CAC 40 in Paris was up 0.2%, while the DAX 40 in Frankfurt was up 0.3%.

Shares in Tesla were up 5.2% in Frankfurt after the US automaker said deliveries in the second quarter beat market estimates.

The electric car maker delivered 466,140 vehicles, an 83% increase year-on-year and above estimates of 450,000.

"The electric vehicle giant has benefitted from US federal credits which are designed to encourage consumers to shift away from diesel and petrol cars," interactive investor's Victoria Scholar said. "Its strategy to cut prices this year has also paid off amid the macroeconomic headwinds but could weigh on profit margins ahead."

Tesla's production is still a long way below that of major car makers such as Toyota, which produced nearly 950,000 vehicles in May alone this year.

In Asia on Monday, markets took their cue from the strong performance on Wall Street, despite some mixed economic data for the region.

The Nikkei 225 index in Tokyo closed up 1.7%, with Toyota up 0.7%.

In China, the Shanghai Composite closed up 1.3%, while the Hang Seng index in Hong Kong was up 2.3%. The S&P/ASX 200 in Sydney closed up 0.6%.

Early economic data pointed towards a slowdown in Asian manufacturing.

The Caixin purchasing managers' index for China's manufacturing indicated marginal growth in June, albeit at a slower pace than in May. Meanwhile, the au Jibun Bank PMI for Japan showed its manufacturing sector slipped back into a slight contraction. Respondents in Japan noted especially weak demand from mainland China, with exports orders continuing to fall.

In the US on Friday, Wall Street ended higher, with the Dow Jones Industrial Average up 0.8%, the S&P 500 up 1.2% and the Nasdaq Composite up 1.5%. Sentiment was lifted by a cooler-than-expected US inflation print, which boosted hopes that the Federal Reserve's rate-rising spree might be close to an end.

Still, the dollar was firm against other major currencies in early exchanges in Europe on Monday.

Sterling was quoted at USD1.2670, lower than USD1.2706 at the London equities close on Friday. The euro traded at USD1.0880, lower from USD1.0916. Against the yen, the dollar was quoted at JPY144.75, up versus JPY144.58.

In London, supermarket chain Tesco rose 0.9% as it named Gerry Murphy as its new chair from September 1.

Murphy is currently chair of luxury fashion firm Burberry and food supplier Tate & Lyle, and will step down from his role at the latter to "ensure he has sufficient capacity" for his new role at Tesco.

Murphy was also previously CEO at Kingfisher, and has held non-executive directorships at companies including British American Tobacco and Reckitt Benckiser.

Shares in Tate & Lyle fell 0.5%, while Buberry was trading flat.

Anglo American rose 2.3%, as it announced late on Friday that its diamond business, de Beers, reached an eleventh-hour deal with the Botswanan government. This followed months of tense negotiations that saw the continent's top producer threatening to cut ties with the storied diamond company.

The Botswana government and Anglo-American, have reached an "agreement in principle", the two sides said in a statement issued late Friday. The agreement provides for a new 10-year agreement to sell the rough diamonds produced by Debswana – a joint venture equally owned by the government and De Beers – and a 25-year extension of its mining licenses.

AstraZeneca fell 5.9% in early trade - the worst large-cap performer - as it announced high-level results from the Tropian-Lung01 phase III trial.

The trial looked at datopotamab deruxtecan, or Dato-DXd, in advanced non-small cell lung cancer. In patients will locally advanced or metastatic NSCLC treated with at last one prior therapy, the treatment showed a "statistically significant" improvement for the dual primary endpoint of progression-free survival compared to docetaxel, the current standard of care chemotherapy.

However, for the dual primary endpoint of overalll survival, the data "were not mature".

"An early trend was observed in favour of datopotamab deruxtecan versus docetaxel that did not meet the prespecified threshold for statistical significance at this interim analysis," AstraZeneca said.

The trial will continue as planned in order to assess OS with greater security.

On AIM, Yourgene Health more than doubled in value, with its shares reaching 0.47 pence from 0.20p on Friday.

The molecular diagnostic group has agreed a cash takeover offer with Novacyt UK, a wholly-owned subsidiary of fellow AIM listing Novacyt. The offer of 0.522p a share values the company at GBP16.7 million.

Novacyt is a biotechnology group focused on clinical diagnostics. Its shares were up 16%.

"The acquisition combines highly complementary technologies and services, with the enlarged group able to leverage mutual research and development capabilities for ongoing product development and portfolio enhancement to improve the customer offering," the companies said.

Gold was quoted at USD1,916.08 an ounce early Monday, higher than USD1,915.48 on Friday. Brent oil was trading at USD75.28 a barrel, little changed from USD75.58

There are more manufacturing PMI readings to come, including the UK at 0930 BST and the US at 1445 BST.

Financial markets in New York close at 1300 local time on Monday for Independence Day. They stay closed on Tuesday for the US public holiday.

By Elizabeth Winter, Alliance News senior markets reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
Today 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
Today 09:27

AstraZeneca completes USD2.4 billion Fusion Pharmaceuticals purchase

(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals Inc.

Read more
3 Jun 2024 08:59

AstraZeneca cancer treatment Tagrisso recommended for approval in EU

(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the European Union.

Read more
3 Jun 2024 07:28

AstraZeneca's lung cancer treatment recommended for approval in EU

(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommended for approval by European regulators.

Read more
2 Jun 2024 20:03

Astra's Enhertu breast cancer trial shows 'unprecedented' results

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy - even if they had very low levels of the mutant protein targeted by the drug, according to trial results announced on Sunday.

Read more
2 Jun 2024 15:58

Astra's Enhertu delays breast cancer in patients with low HER2 levels

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to delay the growth of hormone-sensitive breast cancer by about five months for people with low levels of HER2 protein whose cancer progressed following endocrine therapy, according to research presented on Sunday.

Read more
30 May 2024 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

Read more
30 May 2024 07:40

LONDON BRIEFING: Dr Martens cuts payout as profit plummets

(Alliance News) - Stocks in London are called to open lower on Thursday, with investors nervous ahead of Friday's US inflation print.

Read more
29 May 2024 08:54

IN BRIEF: AstraZeneca drug lowers cholesterol in phase 1 trial

AstraZeneca PLC - Cambridge, England-based pharmaceuticals - Reports positive results in a phase 1 trial of cholesterol drug candidate AZD0780, an oral small molecule PCSK9 inhibitor. Administered on top of rosuvastatin treatment, AZD0780 showed a statistically significant reduction in low-density lipoprotein cholesterol in plasma for test participants with hypercholesterolaemia, Astra says, while no serious adverse events were reported. "Elevated LDL-C levels in plasma is a key risk factor for cardiovascular disease and is estimated to cause 2.6 million deaths worldwide annually," Astra notes.

Read more
28 May 2024 07:02

AstraZeneca experimental lung cancer drug shows promising results

(Sharecast News) - AstraZeneca's experimental lung cancer drug showed improved overall survival rates in phase III trials, the pharmaceutical giant said on Tuesday.

Read more
27 May 2024 07:49

IN BRIEF: Astra, Daiichi hail positive survival data for Dato-DXd

AstraZeneca PLC - Cambridge, UK-based pharmaceutical firm - Alongside Japan's Daiichi Sankyo Co Ltd, notes positive data for datopotamab deruxtecan in phase III trial on lung cancer. Says the treatment, also known as Dato-DXd, showed a clinically meaningfully improvement in overall survival versus chemotherapy in advanced nonsquamous non-small cell lung cancer. The results build upon the positive progression-free survival findings presented back in 2023, Astra adds.

Read more
22 May 2024 09:53

LONDON BROKER RATINGS: Barclays cuts NextEnergy but lifts JLEN

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
22 May 2024 02:00

British firms expecting hard time in China market, lobby group warns

BEIJING, May 22 (Reuters) - British firms expect doing business in China to become harder over the next five years, a British business lobby group said on Wednesday, as Beijing strives to halt a retreat in foreign funds from a market once seen as the engine of global growth.

Read more
21 May 2024 19:00

Sector movers: Stocks slip amid light profit-taking

(Sharecast News) - Stocks ended a tad lower as investors waited on a raft of US central bank speakers scheduled for after the close of markets in London.

Read more
21 May 2024 17:20

Europe's STOXX 600 ends lower as rate uncertainty prevails

Focus on Fed minutes, Nvidia earnings

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.